Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03106571 · ClinicalTrials.gov registry record · Phase 1
Study of Pomaglumetad and Methamphetamine
A Phase 1 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03106571 is a Phase 1 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 19 participants.
The verdict
NCT03106571, a Phase 1 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is the first study of pomaglumetad in humans using methamphetamine. The goal of the study is to determine if pomaglumetad is safe when administered with methamphetamine. If shown to be safe with methamphetamine in the current study, a phase 2 clinical trial of pomaglumetad would be done to begin to find out if pomaglumetad is effective in treating methamphetamine use disorder.
Interventions
- DRUG Placebo
- DRUG Methamphetamine
- DRUG Pomaglumetad methionil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03106571
The ClinicalTrials.gov registry entry for NCT03106571 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03106571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03106571 about?
NCT03106571 is a clinical study titled "Study of Pomaglumetad and Methamphetamine". This is the first study of pomaglumetad in humans using methamphetamine. The goal of the study is to determine if pomaglumetad is safe when administered with methamphetamine. If shown to be safe with methamphetamine in the current study, a phase 2 clinical trial of pomaglumetad would be done to begi...
What is the current status of trial NCT03106571?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2017-08-01. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03106571?
The interventions under investigation include: Placebo (DRUG), Methamphetamine (DRUG), Pomaglumetad methionil (DRUG).
Who is sponsoring clinical trial NCT03106571?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.